These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28328527)

  • 21. Beta spending function based on conditional power in group sequential design.
    Ni S; Zhong Z; Jiang Z; Zhao Y; Wu J; Yu H; Bai J
    Biom J; 2024 Apr; 66(3):e2300094. PubMed ID: 38581099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: a resampling approach.
    Yi J; Fang L; Su Z
    Contemp Clin Trials; 2012 Jan; 33(1):138-42. PubMed ID: 21983624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A generalized F mixture model for cure rate estimation.
    Peng Y; Dear KB; Denham JW
    Stat Med; 1998 Apr; 17(8):813-30. PubMed ID: 9595613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fitting parametric cure models in R using the packages cuRe and rstpm2.
    Jensen RK; Clements M; Gjærde LK; Jakobsen LH
    Comput Methods Programs Biomed; 2022 Nov; 226():107125. PubMed ID: 36126436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A SAS macro for parametric and semiparametric mixture cure models.
    Corbière F; Joly P
    Comput Methods Programs Biomed; 2007 Feb; 85(2):173-80. PubMed ID: 17157948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superiority of combining two independent trials in interim futility analysis.
    Deng Q; Zhang YY; Roy D; Chen MH
    Stat Methods Med Res; 2020 Feb; 29(2):522-540. PubMed ID: 30957713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two-stage adaptive design for clinical trials with survival data.
    Li G; Shih WJ; Wang Y
    J Biopharm Stat; 2005; 15(4):707-18. PubMed ID: 16022174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sample size determination for an exponential survival model with an unrestricted covariate.
    Zhen B; Murphy JR
    Stat Med; 1994 Feb; 13(4):391-7. PubMed ID: 8177988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal conditional error functions for the control of conditional power.
    Brannath W; Bauer P
    Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective analysis of conditional power assumptions in clinical trials with continuous or binary endpoints.
    Edwards JM; Walters SJ; Julious SA
    Trials; 2023 Mar; 24(1):215. PubMed ID: 36949524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data.
    Shimura M; Gosho M; Hirakawa A
    Stat Med; 2017 Jun; 36(13):2067-2080. PubMed ID: 28211076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The reassessment of trial perspectives from interim data--a critical view.
    Bauer P; Koenig F
    Stat Med; 2006 Jan; 25(1):23-36. PubMed ID: 16220517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early stopping in clinical trials and epidemiologic studies for "futility": conditional power versus sequential analysis.
    van der Tweel I; van Noord PA
    J Clin Epidemiol; 2003 Jul; 56(7):610-7. PubMed ID: 12921928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mixture and non-mixture cure fraction models based on the generalized modified Weibull distribution with an application to gastric cancer data.
    Martinez EZ; Achcar JA; Jácome AA; Santos JS
    Comput Methods Programs Biomed; 2013 Dec; 112(3):343-55. PubMed ID: 24008248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cure modeling in real-time prediction: How much does it help?
    Ying GS; Zhang Q; Lan Y; Li Y; Heitjan DF
    Contemp Clin Trials; 2017 Aug; 59():30-37. PubMed ID: 28545934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mixture Cure Models in Oncology: A Tutorial and Practical Guidance.
    Felizzi F; Paracha N; Pöhlmann J; Ray J
    Pharmacoecon Open; 2021 Jun; 5(2):143-155. PubMed ID: 33638063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conditional power in vaccine trials with seasonal variations.
    Tang X; Yan LK; Scott JA
    J Biopharm Stat; 2022 May; 32(3):427-440. PubMed ID: 35767382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimating and modeling the cure fraction in population-based cancer survival analysis.
    Lambert PC; Thompson JR; Weston CL; Dickman PW
    Biostatistics; 2007 Jul; 8(3):576-94. PubMed ID: 17021277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges in Implementing Futility Schemes, with Reference to Aducanumab.
    Gallo P; Roychoudhury S
    Ther Innov Regul Sci; 2023 May; 57(3):515-520. PubMed ID: 36735195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.